Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

1.3K
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
1.3K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

380
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
380
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

26
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
26
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

34
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
34

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human immunodeficiency virus (HIV) and coronavirus disease 2019; impact on vulnerable populations and harnessing lessons learnt from HIV programmes.

New microbes and new infections·2021
Same author

Colonoscopic techniques in polyp detection: An Egyptian study.

Revista de gastroenterologia de Mexico (English)·2020
Same author

Preoperative estimation of cosmetic outcomes after immediate breast reconstruction with extended latissimus dorsi flap: A simple prediction model.

JPRAS open·2020
Same author

Whole-genome sequencing of human Pegivirus variant from an Egyptian patient co-infected with hepatitis C virus: a case report.

Virology journal·2019
Same author

Association of genetic polymorphisms of chemokines and their receptors with clearance or persistence of hepatitis C virus infection.

British journal of biomedical science·2018
Same author

The association of single nucleotide polymorphisms of Toll-like receptor 3, Toll-like receptor 7 and Toll-like receptor 8 genes with the susceptibility to HCV infection.

British journal of biomedical science·2018

Related Experiment Video

Updated: Apr 27, 2026

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI
06:09

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI

Published on: July 21, 2023

2.2K

CUFA algorithm: assessment of liver fibrosis using routine laboratory data.

H Shehab1, I Elattar, T Elbaz

  • 1Department of Endemic medicine, Hepatology Division, Faculty of medicine, Cairo University, Cairo, Egypt.

Journal of Viral Hepatitis
|July 4, 2014
PubMed
Summary

A new, cost-effective noninvasive method using routine lab tests and clinical data can accurately stage liver fibrosis in HCV patients. The CUFA algorithm reduces the need for invasive liver biopsies and expensive tests.

Keywords:
CUFA algorithmHCVPLASA score.chronic hepatitis Cfibrosislivernoninvasive

More Related Videos

Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy
10:10

Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy

Published on: July 20, 2022

5.7K
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

1.2K

Related Experiment Videos

Last Updated: Apr 27, 2026

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI
06:09

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI

Published on: July 21, 2023

2.2K
Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy
10:10

Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy

Published on: July 20, 2022

5.7K
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

1.2K

Area of Science:

  • Hepatology
  • Biochemistry
  • Clinical Diagnostics

Background:

  • Liver fibrosis staging is crucial for managing Hepatitis C Virus (HCV) infection.
  • Liver biopsy, the gold standard, is invasive and prone to sampling errors.
  • Existing noninvasive methods are often costly and complex.

Purpose of the Study:

  • To develop a novel, noninvasive method for staging liver fibrosis using only routine laboratory tests and clinical data.
  • To create a cost-effective diagnostic tool for liver fibrosis assessment in HCV patients.

Main Methods:

  • Collected clinical and laboratory data from 994 HCV patients with liver biopsies.
  • Utilized logistic regression to develop a predictive model (PLASA: platelets, AST, age) for significant fibrosis (≥F2).
  • Developed a sequential diagnostic algorithm (CUFA) combining APRI with the PLASA model.

Main Results:

  • The PLASA model demonstrated good predictive performance (AUC 0.753-0.777) in training and validation sets.
  • The CUFA algorithm significantly reduced the need for liver biopsies by 20% for significant fibrosis and 34% for cirrhosis.
  • CUFA outperformed other noninvasive markers like APRI and FIB-4 in predicting fibrosis stages.

Conclusions:

  • The CUFA algorithm offers a cost-free, noninvasive approach for initial liver fibrosis assessment in HCV patients.
  • This algorithm can serve as a first-line tool, potentially avoiding more expensive tests or invasive procedures.
  • CUFA enhances patient management by streamlining the diagnostic pathway for liver fibrosis.